降压药依普利酮的价格

(Inspra) is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the State Food and Drug Administration in 2002. Eplerenone binds to the mineralocorticoid receptor, thereby blocking the binding of aldosterone (a component of the renin-angiotensin-aldosterone system (RAAS)). Eplerenone has been used to treat hypertension and left ventricular dysfunction after acute myocardial infarction. It can effectively lower blood pressure, improve cardiac function and reduce myocardial damage.

The commonly used domestic aldosterone receptor antagonist spironolactone has a significant protective effect on the cardiovascular system, but it can also cause central hypertension, accelerate endothelial damage (catecholamines enhance its effect), reduce heart rate variability, induce ventricular arrhythmia, promote sodium retention, potassium and magnesium loss, promote myocardial fibrosis, necrosis and inflammation, and damage the fibrinolytic system. Therefore it is difficult to be widely used.

Eplerenone (Inspra) has extremely low affinity for androgen and progesterone receptors and has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. It is a good alternative to spironolactone.

Eplerenone has been on the market for a long time, and domestic patients are still concerned about its price. Eplerenone is not currently on the market in my country. The price of the original drug in the United States is relatively high. Many patients say that long-term medication requires more costs. In comparison, the Indian version of eplerenone (Inspra) is a better choice for domestic patients.

The Indian version (Inspra) has a specification of 50mg*100 tablets and the price is around 500$. Prices may also change due to exchange rates. Please consult the Medical Companion Travel Service for specific prices.

Recommended related hot articles: /newsDetail/72989.html